---
layout: post
title: "Patient-Focused Drug Development: Methods To Identify What Is Important to Patients; Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability"
date: 2026-02-05 18:58:16 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-04152
original_published: 2022-02-28 00:00:00 +0000
significance: 8.00
---

# Patient-Focused Drug Development: Methods To Identify What Is Important to Patients; Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** February 28, 2022 00:00 UTC
**Document Number:** 2022-04152

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry, FDA staff, and other stakeholders entitled "Patient-Focused Drug Development: Methods To Identify What Is Important to Patients." This guidance (Guidance 2) is the second in a series of four methodological guidance documents that FDA committed to develop to describe how to collect and submit information from patients and caregivers to be used for medical product development and regulatory decision making. This guidance finalizes the draft guidance of the same title issued on October 1, 2019.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/02/28/2022-04152/patient-focused-drug-development-methods-to-identify-what-is-important-to-patients-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-04152

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
